Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133541) titled 'A Study on the Efficacy and Safety of Sonrotoclax Combined with the DCEG Regimen in Patients with TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes' on Sept. 29.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Huadong Hospital
Condition:
TP53-mutated acute myeloid leukemia/myelodysplastic syndrome (TP53-mutated AML/MDS)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-29
Target Sample Size: Decitabine + etoposide (VP?16) + sotuoclax group:35;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showpro...